Martinez-Lostao L - Search Results

1

Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis.

Pawlak A, DE Miguel D, Kutkowska J, Obmińska-Mrukowicz B, Rapak A, Martinez-Lostao L. Pawlak A, et al. Anticancer Res. 2017 Dec;37(12):6655-6665. doi: 10.21873/anticanres.12123. Anticancer Res. 2017. PMID: 29187441

2

APO2L/TRAIL: new insights in the treatment of autoimmune disorders.

Anel A, Martinez-Lostao L. Anel A, et al. Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):184-99. doi: 10.2174/187221311797264883. Recent Pat Inflamm Allergy Drug Discov. 2011. PMID: 21827400 Review.

3

Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.

Martinez-Lostao L, Marzo I, Anel A, Naval J. Martinez-Lostao L, et al. Biochem Pharmacol. 2012 Jun 1;83(11):1475-83. doi: 10.1016/j.bcp.2011.12.036. Epub 2012 Jan 2. Biochem Pharmacol. 2012. PMID: 22230480 Review.

4

Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells.

De Miguel D, Basáñez G, Sánchez D, Malo PG, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L. De Miguel D, et al. Mol Pharm. 2013 Mar 4;10(3):893-904. doi: 10.1021/mp300258c. Epub 2013 Feb 6. Mol Pharm. 2013. PMID: 23331277

5

Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells.

De Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L. De Miguel D, et al. Leuk Res. 2015 Jun;39(6):657-66. doi: 10.1016/j.leukres.2015.03.019. Epub 2015 Apr 4. Leuk Res. 2015. PMID: 25882551

6

Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells.

De Miguel D, Gallego-Lleyda A, Galan-Malo P, Rodriguez-Vigil C, Marzo I, Anel A, Martinez-Lostao L. De Miguel D, et al. Clin Transl Oncol. 2015 Aug;17(8):657-67. doi: 10.1007/s12094-015-1295-x. Epub 2015 May 13. Clin Transl Oncol. 2015. PMID: 25967100

7

Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.

Martinez-Lostao L, de Miguel D, Al-Wasaby S, Gallego-Lleyda A, Anel A. Martinez-Lostao L, et al. Immunotherapy. 2015;7(8):883-2. doi: 10.2217/imt.15.56. Epub 2015 Aug 28. Immunotherapy. 2015. PMID: 26314314 Review.

8

In vivo potential of recombinant granulysin against human tumors.

Al-Wasaby S, de Miguel D, Aporta A, Naval J, Conde B, Martínez-Lostao L, Anel A. Al-Wasaby S, et al. Oncoimmunology. 2015 Jul 1;4(9):e1036213. doi: 10.1080/2162402X.2015.1036213. eCollection 2015 Sep. Oncoimmunology. 2015. PMID: 26405603 Free PMC article.

9

Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.

De Miguel D, Gallego-Lleyda A, Ayuso JM, Pawlak A, Conde B, Ochoa I, Fernández LJ, Anel A, Martinez-Lostao L. De Miguel D, et al. Recent Pat Anticancer Drug Discov. 2016;11(2):197-214. doi: 10.2174/1574892811666160229121544. Recent Pat Anticancer Drug Discov. 2016. PMID: 26924736

10

Onto better TRAILs for cancer treatment.

de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. de Miguel D, et al. Cell Death Differ. 2016 May;23(5):733-47. doi: 10.1038/cdd.2015.174. Epub 2016 Mar 4. Cell Death Differ. 2016. PMID: 26943322 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters